...Contents Business sector What is the main business of the group? Are there other activities, complementary businesses within the group? What are the main group's competitors? Which main risks (that are inherent to this business sector) does the company mention? Which hedging policies are put in place? Profitability Which indicators have been brought forward in the annual report of the company? Which specific targets are aimed at? How does the group state and assess the evolution of profitability in the annual report? Is there more recent public information about this issue? Where? Is this information in line with the one mentioned in the annual report? Is it indicating a similar evolution? What are the main propositions of the company to improve its profitability? Financing What is the global financing strategy of the group? What is the evolution of the financing cost (several indicators)? What is the shareholders’ remuneration program? What are your sources (of information) regarding this issue? Investments What are the main investment / disinvestment policies? How are these investments financed? What is the outlook of the company regarding this issue? Consolidation process What are the most important consolidated subsidiaries? (Eventually mention the approximate number of subsidiaries)? Are there associated companies? What is the evolution...
Words: 9147 - Pages: 37
...Analysis and interpretation of company’s financial Tutor: Richard Pennington Submitted by: Ming Zhi: 5515543 Group members: Chang Zhang: 5979309 Ming Zhi: 5515543 Lu Cao: 5949139 Ya Lei Qiang: 4119832 Xuechen Wang: 6443412 Table of content 1. Background information 3 1.1 Bayer 3 1.2 Johnson & Johnson 4 2. Vertical and horizontal analysis 5 2.1 Bayer’s Horizontal Analysis of the Income Statement 5 2.2 Johnson & Johnson 10 3. Ratio analysis 15 3.1 Profitability 15 3.2 Liquidity ratios 16 3.3 Efficiency 17 3.4 Gearing 18 3.5 Investment 19 4. Recommend and explain which company is more attractive to invest in 20 4.1 Profitability 20 4.2 liquidity position 21 4.3 turnover rate 21 4.4 leverage 22 4.5 earning for shareholders 22 4.6 Market prediction and analysts’ view 22 4.7 conclusions 23 5. Limitations of ratio analysis 23 1. Background information 1.1 Bayer Bayer is a German chemical and pharmaceutical company which is founded in Barmen Germany in 1863. At present, Bayer is a global enterprise with major business domains ishealth care, agriculture and high tech polymer materials. Bayer AG, Leverkusen, Germany, acts as a strategic management holding company. It shoulders whole company’s values, goals and strategies. It is also responsible for resource allocation and managerial appointments (Bayer 2014). Led by Bayer AG, the HealthCare, CropScience and MaterialScience subgroups independently manage their business...
Words: 6320 - Pages: 26
...The Analysis of Bayer’s Sustainability Report Introduction Nowadays it is becoming accepted that entities also have responsibilities to a broader group of stakeholders (e.g. local communities, customers, employees, government and even future generations) compared to the traditionally business corporations just perceived to be responsible for their financial performance and that the principal shareholders were the owners. Most of the companies now being held responsible for their social and environmental as well as their financial performance. This paper has been treated with an in-depth analysis of Bayer’s sustainability report. Firstly, a briefly introduction of Bayer would be presented, including the organization’s business, its mission and objectives and states how these are related with their social and environmental goals. In addition, based on the information in the annual report provided to select three unique initiatives that are crucial to the core business, then evaluate each point respectively. What’s more, each of them related to the company’s performance would be assessed. Finally, the project sought to recommend possible improvements in the initiatives chosen in terms of the form and the content of the element discussed. Other good performance indicators compared to Bayer’s performance used by competitors would be listed as well. Case Study I Bayer is a Life Science enterprise with a more than one hundred and fifty years histories and core competencies in...
Words: 1473 - Pages: 6
...reasons for this paradigm shift is the near constant rise of the cost of energy. In the case of a large company like Bayer, one of the most significant energy cost is linked to the use of its data center. Because Bayer is a company whose success depends on the preservation of its intellectual property, they absolutely must keep their privileged information in their own data center and this data needs to have a high level of redundancy to make it reliable (Smith, 2011). A global analysis of the costs of running Intel based data centers, which is the dominant company used in the field, has shown a rise of 400% of the costs linked to cooling and power. This modern dilemma brings forth a brand new kind of trade-off, save costs without sacrificing reliability. This situation can be easily understood when you know that: “93% of companies that lost access to their corporate data centre for ten days or more due to a disaster filed for bankruptcy within one year of the disaster; with 50% of businesses that found themselves without data management for this same time period filed also filed for bankruptcy” (Smith, 2011). This situation is sadly not easily avoidable, research has shown that in 2011, 70% of the data centers experienced disruption related to power usage at enormous costs in productivity loss and technical support (Hengst, 2008). One of the reasons we have chosen Bayer for our study is that it is a proven trailblazer when it comes to improving its processes and efficiently using...
Words: 796 - Pages: 4
...Liability of Bayer Pharmaceuticals The Bayer Pharmaceuticals Company was founded in 1893 by Friedrich Bayer and Johann Wescott in Barmen, Germany. Bayer is known for their trademarked Bayer Aspirin which was created in 1899. Bayer spent decades marketing heroin worldwide as a cough medicine for children. The side effects of selling heroin to children were not a concern for them. Although they originated as a pharmaceutical company they turned their attention to manufacturing chemical weapons. Bayer formed a close relationship with German firms during the World War which formed the conglomerate called IG Farben. They became the largest donor to Hitler’s army. In the post-war years Bayer grew to become the third largest pharmaceutical company in the world. In the mid-1980s Bayer was one of the companies which sold a product called Factor VIII concentrate to treat haemophilia. Factor VIII turned out to be infected with HIV and in the U.S. alone; it infected thousands of haemophiliacs, many of whom died in one of the worst drug-related medical disasters ever. But it was only in 2003 that the New York Times revealed that Bayer had continued producing and selling this infected product to Asia and Latin America after February 1984 when a safe product had become available, in order to save money. Dr. Sidney M. Wolfe, who investigated the scandal, commented, "These are the most incriminating internal pharmaceutical industry documents I have ever “(Bayer:history,2012) Bayer has been...
Words: 2126 - Pages: 9
...As Bayer approached its first quarter in April 2010, chief executive officer Dr. Marijin Dekkers explained that “Bayer operating performance was back on track, compared with the crisis year 2009”. Bayer Group had sales of $35.1 billion. Clearly, 2010 was a successful year for Bayer in terms of business expansion and growth. The group examined Bayer financial statements to determine if the picture presented by Dekker is reflected in the financial performance of the firm by examining financial ratios using information from the Income statement and balance sheet. Financial ratios help to identify some of the financial strength and weakness of firms. The ratios give us two ways on making meaningful comparisons of the financial data. First, we examined the ratios across time ( for example, five years) to identify trends and we can compare the firm’s ratio with those of other firms. This financial analysis will allows us to see if Bayer is as good as management claims it to be. Analysis of Financial Ratios Bayer’s sales increased by 12.6% from 2009 to 2010, after dropping 5.3% from 2008 to 2009. However, Bayer’s gross profit margin remained stable, increasing from 47.20% in 2006, 49.50% in 2007, 50.00% in 2008, 51.44% in 2009 and 51.50% in 2010. On the other hand, Bayer net profit margin decreased over the same period, falling from 10.77% in 2008 to 9.64% in 2009 to 7.78% in 2010. The decrease in 2010 is more significant than the previous years, this is caused...
Words: 2714 - Pages: 11
...Strategic Analysis of Syngenta Jolly was a young, bright girl, studying her Bachelor of Business Administration. When she came home from college, her mind was occupied by the assignment given to her in her Business Strategy Class. She had to pick up a company of her choice and complete strategic analysis, over a period of three years, consisting of size of the organization, financial performance, operational performance, some tailored measures of performance relating to the organization’s industry, competitor analysis, strategic actions of the organization, and strategic issues faced. She thought that she would figure out what procedure to follow from her prescribed textbook ‘Strategic Management – Theory and Application,’ by Adrian Haberberg & Alison Rieple. After a certain thought, she chose Syngenta – headquartered at Basel, Switzerland. Jolly referred to the textbook and jotted down the procedure as below. Procedure for doing the Strategic Analysis: 1) Evaluate financial performance: Calculate the following quantities and analyze them and find out the trend in the last three years. Overall Sales Overall Profit Profitability ratios such as Return on Equity (ROE), Return on Assets (ROA), and Return on Capital Employed(ROCE). 2) Measure operational performance: Page 1 of 29 Calculate the following quantities; find out the trend and analyze: Operating profit Operating profit as a percentage of sales (profit margin) Sales per employee Operating profit per employee ...
Words: 6884 - Pages: 28
...unavoidable incidences of the very many cancers affecting people in Ireland today is an area of medicine which harnesses, in union with pharmaceutical products, the skills of Specialist Consultant Oncologists at the very highest level. Bayer is an established link in this chain principally through the proven use of its product Nexavar, which is currently licensed for the treatment of kidney and liver cancers. It is anticipated however that Nexavar’s scope will be extended to include its use in further indications in Oncology subject to positive phase III clinical trial results. All of this theatre of activity, from the viewpoints of the medical practitioners, the regulatory agencies and the pharmaceutical companies, is necessarily driven by the continuum of verified product trial statistical endpoints. While the market for pharmaceutically assisted weight-loss products is both extensive and growing, it remains fundamentally different from cancer therapies in that overweight individuals have realistically much more discretion with regard to the decision as to what if anything to choose from within the wide menu of discretionary weight-loss products, while cancer sufferers firstly must attend specialist Oncology consultants whose diagnostic analysis will determine what if any Oncology treatment may be suitable and secondly, being a life-threatening condition, cancer requires immediate urgent non-discretionary specialist care. While Nexavar currently is licensed for two indications...
Words: 1504 - Pages: 7
...products and others related to them are responsible for over 16,500 deaths annually in the United States alone. The side effects of NSAIDs are kidney and liver damage, blood disorders, heart attacks, strokes, hypertension, bleeding ulcers and serious interactions with other drugs. (Washington Post) It is imperative that researchers of Bayer find a solution for this problem that will ease the concerns of the consumer, as well as boost sales for Bayer. 1. Company Overview: Bayer was founded in 1863 in Barmen Germany by Friedrich Bayer and Friedrich Weskott. Today, Bayer currently ranks among the top consumer healthcare organizations world wide, and its mission statement is to provide quality healthcare products to their consumers. Bayer exists to attract and retain customers. Bayer is a global enterprise with core competencies in the fields of health care, nutrition, and high tech materials. As an inventor organization it sets a general direction of movement in research – intensive areas, and innovation is the key driver of Bayer’s future growth. Bayer’s products are formulated to benefit consumers, while improving the quality of life. Bayer is portrayed globally by approximately 300 companies and is headquartered in Leverkusen Germany. (Business week) Bayer’s Health Care segment is driven primarily by its pharmaceutical establishment but also includes its Customer Care...
Words: 2606 - Pages: 11
... |Law |5 | |4 |Analysis |7 | |5 |Appendix | | | |Article 1 |9 | | |Article 2 |14 | | |Article 3 |18 | | |Article 4 |23 | | |Article 5 |25 | | |Article 6 |27 | Introduction The topic for my current events paper is the “Re Genetically Modified” rice litigation against Bayer Corporation - one of...
Words: 7100 - Pages: 29
...the many products sold are certainly many benefits. As we know there are many companies working in this field. Among the companies that are well known, namely Bayer Healthcare, Johnson & Johnson, Pfizer, Novartis, Hoffmann-La Roche, GlaxoSmithKline, Sanofi-Aventis and many more. The names of these companies are not necessarily familiar to the public. Among the names of global pharmaceutical companies are already very well known, many of which are based in United States. With reasonable price, not too expensive or cheap and very easy to find. Medicinal products from global pharmaceutical companies to be very favorite countries in the world. But of course if explored further, something will have positive and negative, strengths and weaknesses also have external influences whether it be an opportunity or a threat. In this paper will explain a little about the SWOT analysis of the global pharmaceutical companies along with solutions and recommendations. 2. SWOT Analysis SWOT analysis is the analysis of situations and conditions that are descriptive (illustrate). This analysis puts the situation and condition as a factor inputs, which are then grouped according to their respective contributions. One thing must be remembered well by the users of the SWOT analysis, the SWOT analysis is merely a tool of analysis aimed to describe the situation at hand or that may be faced by the...
Words: 1624 - Pages: 7
...PHARMACEUTICAL INDUSTRY RESEARCH PAPER Submitted By RAKESHKUMAR PATEL NILAMBEN PATEL MONROE COLLEGE NOVEMBER 19, 2012 MG 620 RESEARCHES FOR STATISTICS Presented to DR. ANNE WALSH ABSTRACT The United States is the world’s largest market for pharmaceuticals and the world leader in biopharmaceutical research. U.S. firms conduct 80 percent of the world’s research and development in biotechnology and hold the intellectual property rights to most new medicines. In 2010, the pharmaceutical sector employed approximately 272,000 people (source: Bureau of Labor Statistics), and according to the Pharmaceutical Research and Manufacturers of America (Parma), those manufacturers spent $67.4 billion on research and development in 2010. The markets for biologics, over-the-counter (OTC) medicines, and generics show the most potential for growth and have become increasingly competitive. Biologics, valued at $67 billion in 2010 (source: IMS Health), account for a quarter of all new drugs in clinical trials or awaiting Food and Drug Administration approval. OTC market growth will be driven by a growing aging population and consumer trend to self-medication and the conversion of drugs from prescription to non-prescription or OTC status. Generic drug sales in the United States were valued at $78 billion in 2010 (source: IMS Health). The U.S. market is the world’s largest free-pricing market for pharmaceuticals and has a favorable patent...
Words: 3366 - Pages: 14
...please contact the Indiana Economic Development Corporation’s Office of International Trade at 317.232.4949. Direct questions to the authors of the report to Larry Davidson at davidso@indiana.edu or 812.855.2773. Introduction This paper summarizes the results of our global pharmaceutical industry analysis and is intended to increase awareness of the general public – investors, policy makers, managers, employees of the companies – about its current developments. The paper has the following major goals: 1) To analyze the current situation, major challenges and the prospects of the pharmaceutical industry; 2) To identify major players of the global pharmaceutical industry and make a comparative analysis of their business practices and financial results; 3) To determine the relative position of the U.S. pharmaceutical companies in the global pharmaceutical industry, as well as to reveal opportunities for further strengthening of their positions. The paper consists of three major parts. In the first part we present an overview of the pharmaceutical industry as a whole – its major players, current trends and challenges. The second part focuses on a more detailed analysis of major pharmaceutical...
Words: 10094 - Pages: 41
...please contact the Indiana Economic Development Corporation’s Office of International Trade at 317.232.4949. Direct questions to the authors of the report to Larry Davidson at davidso@indiana.edu or 812.855.2773. Introduction This paper summarizes the results of our global pharmaceutical industry analysis and is intended to increase awareness of the general public – investors, policy makers, managers, employees of the companies – about its current developments. The paper has the following major goals: 1) To analyze the current situation, major challenges and the prospects of the pharmaceutical industry; 2) To identify major players of the global pharmaceutical industry and make a comparative analysis of their business practices and financial results; 3) To determine the relative position of the U.S. pharmaceutical companies in the global pharmaceutical industry, as well as to reveal opportunities for further strengthening of their positions. The paper consists of three major parts. In the first part we present an overview of the pharmaceutical industry as a whole – its major players, current trends and challenges. The second part focuses on a more detailed analysis of major pharmaceutical...
Words: 10094 - Pages: 41
...Week 1 |[pi|Week 1: Business Ethics and International Responsibility (May 1 - May 8) | | |[pic]|Help |[p| |c][| | | | | |ic| |pic| | | | | |] | |] | | | | | | | | | | Week 1 Introduction Hi! It's Week 1, and we're set to go. This course is perhaps a little different from the typical MBA course. Rather than studying the internal workings of a business, we shall instead delve into the legal, political, and social cultures of our city, nation, and world and see how these affect everything we do in business. We shall study the gamut of legal concepts, from product liability, to civil rights, to intellectual property rights, to antitrust and consumer protection. Underpinning all of these legal concepts, however, will be two foundational aspects: (a) the ethical issues within, and (b) the "world view" without. Milton Friedman, Immanual Kant, Blanchard and Peale, Laura Nash . . . these are just a few of the names of ethicists and...
Words: 32680 - Pages: 131
